This is an important CORRECTION
: We have been informed that the state supported Regional Infusion Center (RIC) is NOT able to accept Post Exposure Prophylaxis referrals
due to limited physical resources. At this time, the RIC can only provide REGEN-COV MAB infusions to qualifying COVID+ patients.
Although, this vital treatment is now EUA (Emergency Use Approved) for post exposure prophylaxis, the details of administration for this new use still need to be ironed out. Rest assured that your leadership is working closely with all involved to facilitate this process, and I hope to have better news for you soon. Meanwhile, please continue to refer your high risk COVID+ patients for MAB as early in the illness as possible to reduce disease progression.
On a positive note, TCMS and Dell Medical School will host a Special Virtual Town Hall to provide more information and answer questions about Who-to-refer and How-to-refer to the RIC along with a tutorial on MAB infusion. Invitation to follow.
The Corrected RIC referral information is detailed below.
Thank you for your patience and understanding,
Nancy Thorne Foster, MD
Referral Form: Statewide-RIC-Infusion-Referral-Form.pdf
Infusion Hotline (for
Email (to email referral): InfusionReferral@bcfs.net
Fax Number (to fax referral):
Go to Statewide-RIC-Infusion-Referral-Form.pdf
(catrac.org) to access the Referral Form needed to send your patients
for monoclonal antibody infusion therapy. Your patient can be scheduled for their
appointment on Monday through Sunday from 8am to 6pm by calling 1-800-742-5990.
Announcing the opening of a
Regional Infusion Center for Monoclonal Antibody Infusions (MAI) for our
patients. As you know MAI is recommended for eligible COVID-19 positive
patients who are 12 years and older, up to 10 days after symptom onset and for
post exposure prophylaxis.
REGEN-COV is authorized for the
treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and
pediatric patients (12 years of age and older weighing at least 40 kg) with
positive results of direct SARS-CoV-2 viral testing, and who are at high risk
for progression to severe COVID-19, including hospitalization or death.
REGEN-COV can be
given by IV infusion over 20 minutes or by four subcutaneous injections in the
abdomen. Patients are observed for one hour after the medication is